Kala Pharmaceuticals, a Waltham, Mass.-based developer of products that rapidly penetrate the mucosal barrier to treat a wide range of debilitating diseases, has appointed Guillaume Pfefer, PhD, as president, CEO and member of the board of directors.

Pfefer brings to Kala more than 15 years of experience in the pharmaceutical industry leading commercial, strategic, R&D and industrial operations. Prior to joining Kala, he held a number of ascending leadership positions over a nine-year career at Sanofi Pasteur—most recently serving as general manager of Sanofi Pasteur Mexico. Pfefer also previously held executive management positions with Aventis and Rhone-Poulenc.